Literature DB >> 32701563

Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.

Raseen Tariq1,2, Srishti Saha1, Dipesh Solanky1, Darrell S Pardi1, Sahil Khanna1.   

Abstract

BACKGROUND AND GOALS: Clostridioides difficile infection (CDI) recurs in 10% to 15% after fecal microbiota transplantation (FMT). We identify predictors, and describe management and outcome of patients with recurrent CDI after FMT in a predominantly outpatient cohort.
METHODS: A nested case-control study of patients undergoing FMT for recurrent CDI from August 2012 to January 2017 was performed. FMT failure was defined as recurrent diarrhea with positive C. difficile stool test during follow-up (≥2 mo). Controls (patients without FMT failures) were matched to cases 1:1 for sex and timing of FMT±1 month.
RESULTS: Overall, 522 patients underwent FMT; 70 [13.4%; median age 53.8 years (range, 18 to 89 y), 54.3% females] recurred within a median 5.6 months (range, 0.2 to 34.9 mo). Number of prior CDI episodes, prior CDI treatment, and prior CDI-related hospitalizations were similar in cases and controls. Systemic antibiotics after FMT (54.3% vs. 21.4%, P<0.0001), inflammatory bowel disease (IBD) (34.3% vs. 15.7%, P=0.01), pseudomembranes at FMT (4.3% vs. 0%, P=0.03), and poor bowel preparation (68.5% vs. 31.4%, P=0.01) were associated with FMT failure. On multivariate analysis, IBD [odds ratio (OR) 4.34; 95% confidence interval (CI), 1.24-15.15], systemic antibiotics (OR 7.39; 95% CI, 3.02-18.07), and poor bowel preparation (OR 3.84; 95% CI, 1.59-9.28) predicted FMT failure with an area under the curve of 0.78. Among FMT failures, 37 (52.8%) were managed with antibiotics, 32 (45.7%) with repeat FMT after antibiotics and 1 with colectomy.
CONCLUSIONS: Use of systemic antibiotics, IBD, and poor bowel preparation predict FMT failure. Patients with FMT failure can be managed with antibiotics and/or repeat FMT.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 32701563     DOI: 10.1097/MCG.0000000000001398

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

Review 1.  The promise of the gut microbiome as part of individualized treatment strategies.

Authors:  Daniel A Schupack; Ruben A T Mars; Dayne H Voelker; Jithma P Abeykoon; Purna C Kashyap
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

Review 2.  Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.

Authors:  Tae-Geun Gweon; Yoo Jin Lee; Kyeong Ok Kim; Sung Kyun Yim; Jae Seung Soh; Seung Young Kim; Jae Jun Park; Seung Yong Shin; Tae Hee Lee; Chang Hwan Choi; Young-Seok Cho; Dongeun Yong; Jin-Won Chung; Kwang Jae Lee; Oh Young Lee; Myung-Gyu Choi; Miyoung Choi
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

3.  Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?

Authors:  Rahul S Dalal; Jessica R Allegretti
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

4.  Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation.

Authors:  Kosuke Fujimoto; Yasumasa Kimura; Jessica R Allegretti; Mako Yamamoto; Yao-Zhong Zhang; Kotoe Katayama; Georg Tremmel; Yunosuke Kawaguchi; Masaki Shimohigoshi; Tetsuya Hayashi; Miho Uematsu; Kiyoshi Yamaguchi; Yoichi Furukawa; Yutaka Akiyama; Rui Yamaguchi; Sheila E Crowe; Peter B Ernst; Satoru Miyano; Hiroshi Kiyono; Seiya Imoto; Satoshi Uematsu
Journal:  Gastroenterology       Date:  2021-02-09       Impact factor: 22.682

Review 5.  Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice.

Authors:  Maroun Bou Zerdan; Stephanie Niforatos; Sandy Nasr; Dayana Nasr; Mulham Ombada; Savio John; Dibyendu Dutta; Seah H Lim
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.